Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.



In This Section

Research Review


September 2020

This issue of the ACCC Research Review provides support, perspectives, and resources for follow through on the imperative to make clinical trials more inclusive, diverse, accessible, and representative of our patient populations in communities across the country.

While this task can seem overwhelming, let us consider the fact that as oncology professionals, change drives the work we do. Improving rates of screening and early diagnosis, advancing treatments, eliminating health disparities, and reducing the burden of cancer on society—these overarching goals all demand intentional actions and sustained commitment to achieve change.

Read Full Issue

August 2020

Advancing age is the biggest risk factor for cancer. According to the National Cancer Institute, the median age at which cancer is diagnosed in the United States is 66 years. One-quarter of new cancer cases are diagnosed in people aged 65 to 74. An aging population is expanding this demographic trend. By the year 2030, 70 percent of all cancers are expected to occur in adults age 65 and older. Understanding how emerging cancer treatments affect older adults is critical for the delivery of high-quality, patient-centered care.

Yet older adults are consistently precluded from participating in clinical trials for promising new treatments. A 2019 analysis of more than 300 oncology randomized clinical trials found trial participants to be significantly younger than patients in the general population with the same tumor types. Authors of the report published in JAMA Oncology characterize the age disparity they identified as “pervasive and worsening.” In the authors’ analysis of 262,354 participants enrolled in 302 oncology clinical trials between 1994 and 2015, the median age of participants was 6.49 years younger than the median age of other patients with the same cancers.
Read Full Issue

July 2020

Clinical trials need to be more inclusive of Black and African American, Latinx, geriatric patients, and other underserved groups. Equitable representation in and access to cancer clinical trials is essential to truly closing the gap in cancer research.

ACCC has its finger on the pulse of our U.S. oncology community. Top of mind for all of us now are COVID-19, health equity, and expanding the clinical research that continues to improve oncology care for our patients. Based upon the needs and interest of our members, ACCC has selected this year’ president’s theme: Community Oncology Can Close the Gap in Cancer Research: Here’s How.
Read Full Issue